Nek­tar says Eli Lil­ly mis­cal­cu­lat­ed da­ta in eczema tri­al be­fore break­ing off rezpeg part­ner­ship

Nek­tar Ther­a­peu­tics said its for­mer part­ner Eli Lil­ly had pre­sent­ed “er­ro­neous da­ta” for its atopic der­mati­tis drug be­fore break­ing off a $400 mil­lion al­liance.

Where­as the mis­cal­cu­lat­ed Phase Ib da­ta were enough for Nek­tar to move ahead with plans for a Phase IIb study, the biotech said the “new and cor­rect­ed da­ta” sug­gest its can­di­date, rezpe­galdesleukin, had even bet­ter re­sults on the Eczema Area and Sever­i­ty In­dex (EASI). In par­tic­u­lar, Nek­tar un­der­scored that on the high­est dose, rezpe­galdesleukin spurred an 83% im­prove­ment on EASI at 12 weeks, with a p-val­ue of 0.002 com­pared to place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER